BX004 therapy safe and well-tolerated across all patients and dose levels
Preliminary signals of efficacy also observed,withnotable reductionsin bacterial burden
Dosing in patients in Part 2 initiated, results expected in Q323
BiomX Inc a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced positive results from Part 1 of the Phase 1b/2a trial evaluating the Company
